

بسم الله الرحمن الرحيم



-C-02-50-2-





شبكة المعلومات الجامعية التوثيق الالكتروني والميكرونيلم





جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة يعيدا عن الغيار



"Effect of Lisinopril and Verapamil on Angiopoietin-2 and Endostatin in Patients with Diabetic Nephropathy"

Thesis

Submitted for Partial Fulfillment of the Requirements of Master Degree in pharmacy (Biochemistry)

By Mohammed Salem Mohammed El-Melegi

Teaching Assistant of Biochemistry
Faculty of Pharmacy
Ahram Canadian University
Bachelor of Pharmaceutical Sciences
2012

Under Supervion of **Prof. Dr. Hala Osman El-Mesallamy**

Professor of Biochemistry, Faculty of Pharmacy, Ain Shams University Dean of faculty of Pharmacy, Sinai University (Kantara)

Dr. Eman Abd Elaleem Amer


Assistant Professor of Medical Biochemist Faculty of Pharmacy Ahram Canadian University

Dr. Al-Aliaa Mohammed Sallam

Assistant Professor of Biochemistry Faculty of Pharmacy Ain Shams University

Biochemistry Department Faculty of Pharmacy Ain Shams University (Cairo-Egypt) 2021

ACKNOWLEGMENT



Acknowledgment


First of all, I would like to thank **Allah** for his grace and mercy and for giving me the effort to complete this work.

I would like to express my deepest gratitude and great respect to Dr. Hala Osman El-Mesallamy, Professor of Biochemistry and Dean of faculty of Pharmacy, Sinai University (Kantara branch), for her dedicated supervision, precious time, great efforts, faithful advice, continuous unlimited support and encouragement, and kind gestures in every moment throughout all this work that may be added to her good deeds.

I'd like to express my deepest thanks to Dr. Eman Amer, Assistant Professor and Head of the Biochemistry Department, Faculty of Pharmacy, Ahram Canadian University, for her continuous guidance, encouragement, creativity and offering me her precious time for technical experience.

My deepest appreciation goes to Dr. Al Aliaa Mohammed Sallam, Assistant professor of Biochemistry, Faculty of Pharmacy, Ain-Shams University for her valuable suggestions, advice, efforts and for allowing me a free access to her precious time during the accomplishment of this work.


And last but, by no means least, I would like to thank my parents and my family of all their patience, love, support and sacrifice which made this work possible.



LIST OF CONTENTS

| List of Abbreviations | i |
|---|-----|
| List of Tables | iii |
| List of Figures | iv |
| Introduction and Aim of the Work | 1 |
| 2. Literature review | 4 |
| 2.1.Diabetes mellitus | 4 |
| 2.2.Angiogenesis | 20 |
| 3. Subjects and Methods | 26 |
| 3.1. Registration of the clinical trial | 27 |
| 3.2. Subjects | 27 |
| 3.3. Study protocol: | 33 |


| 3.4. Methods | 34 |
|-------------------------|----|
| 4.Results | 60 |
| 5.Discussion | 78 |
| 6.Summary & Conclusions | 86 |
| 7.Recommendations | 92 |
| 8.Appendix | 93 |
| 9.References | 97 |




LIST OF ABBREVIATIONS

| Abbreviation | Definition |
|--------------|--|
| ACEI | Angiotensin-Converting Enzyme Inhibitor |
| ACR | Albumin/Creatinine Ratio |
| AGE | Advanced Glycation End Product |
| Ang-2 | Angiopoietin 2 |
| ARB | Angiotensin-Receptor Blockers |
| AT II | Angiotensin II |
| ССВ | Calcium Channel Blocker |
| CKD | Chronic Kidney Disease |
| DCCT | Diabetes Control and Complications Trial |
| DKD | Diabetic Kidney Disease |
| DM | Diabetes Mellitus |
| DN | Diabetic Nephropathy |
| ECM | Extracellular Matrix |
| ESRD | End Stage Renal Disease |
| EST | Endostatin |
| FDTV | Fixed Dose Trandalopril Verapamil |
| GBM | Glomerular Basal Membrane |
| GFR | Glomerular Filteration Rate |
| HTN | Hypertension |

ı





LIST OF TABLES

| TABLE | TITLE | PAGE |
|-------|--|------|
| NO. | | NO. |
| 1 | Clinical characteristics of type 1 diabetes, type 2 | 8 |
| | diabetes and monogenic diabetes in children and | |
| | adolescents | |
| 2 | Overview of diabetes-related complications | 10 |
| 3 | Diabetic nephropathy stages | 15 |
| 4 | Main clinical and biochemical parameters of the studied | 61 |
| | groups. | |
| 5 | Baseline clinical and laboratory parameters among diabetic nephropathy patients receiving Lisinopril or Lisinopril/ verapamil combination. | 64 |
| 6 | Comparison between diabetic nephropathy patients with lisinopril therapy at baseline and at 3 months follow up. | 65 |
| 7 | Comparison between diabetic nephropathy patients with Lisinopril / verapamil combination therapy at baseline and at 3 months follow up. | 67 |
| 8 | Comparison between diabetic nephropathy group with | 71 |
| ٥ | and without verapamil therapy at the study end | 71 |
| 9 | Percent change of the studied variables among diabetic | 75 |
| | nephropathy patients with Lisinopril and | |
| | Lisinopril/Verapamil combination therapy at study end | |
| 10 | Spearman's correlation coefficient between various | 76 |
| | parameters | |

